Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
Sumitomo Pharma needs to restructure its domestic operations now that it has more or less set the scene for the turnaround of its North American business, Toru Kimura, who was appointed president and CEO on June 25, said to Jiho…
To read the full story
Related Article
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Sumitomo Pharma Replaces CEO amid Dismal Earnings
May 14, 2024
- Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
- Sumitomo’s FY2023 Operating Loss Outlook Swells to 354.9 Billion Yen
May 2, 2024
BUSINESS
- Quviviq Tops Sales Rep Call Ranking for GPs in February: Intage
April 4, 2025
- Merck Biopharma to Develop PharmaMar’s SCLC Drug in Japan
April 4, 2025
- Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll
April 4, 2025
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…